WeVote
Log In

Bill

Bill

HR 1142

To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes.

119th Congress Introduced by David Schweikert

HR 1142 directs HHS to establish drug adherence guidelines for Medicare, aiming for 90% adherence to improve health outcomes and reduce costs for beneficiaries.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 1142

Summary of HR 1142: Drug Adherence Guidelines Act

Purpose and Intent

HR 1142 aims to amend the Public Health Service Act by directing the Secretary of Health and Human Services (HHS) to establish drug adherence guidelines. The primary goal of these guidelines is to achieve a 90% adherence rate for all drugs covered under Medicare Part B and Part D. This initiative seeks to enhance medication adherence among beneficiaries, ultimately improving health outcomes and reducing healthcare costs.

Key Provisions

The bill includes several significant provisions:

  1. Establishment of Drug Adherence Guidelines:

    • The Secretary of HHS is tasked with creating guidelines aimed at achieving a 90% adherence rate for Medicare Part B and D drugs.

  2. Incorporation of Technology:

    • The guidelines must incorporate artificial intelligence (AI) and machine learning (ML) technologies to optimize adherence strategies.

  3. Promotion of Cost-Effective Medications:

    • The guidelines should promote the use of generic and biosimilar drugs to ensure that patients have access to affordable medication options.

  4. Definitions:

    • The bill clarifies terms related to Medicare drugs:
      • Medicare Part B drug: A drug or biological product eligible for payment under Part B of Title XVIII of the Social Security Act.
      • Medicare Part D drug: A covered drug as defined in Section 1860D–2(e) of the Social Security Act.

Affected Parties

The implementation of HR 1142 would primarily affect:
- Medicare beneficiaries: Patients who rely on Medicare Part B and D for their medications.
- Healthcare providers: Physicians and pharmacists who will need to adapt to the new adherence guidelines.
- Pharmaceutical companies: Manufacturers of both brand-name and generic drugs, as the guidelines will promote the use of generics and biosimilars.

Procedural Aspects

  • Introduced: February 7, 2025
  • Current Status: The bill has been referred to the House Committee on Energy and Commerce for further consideration.

Conclusion

HR 1142 represents a proactive approach to improving medication adherence among Medicare beneficiaries through the integration of advanced technologies and a focus on cost-effective drug options. If enacted, it could lead to significant improvements in patient health outcomes and overall healthcare efficiency.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.